| Aug 10 |
Dianthus Therapeutics Second Quarter 2024 Earnings: Beats Expectations
|
| Aug 9 |
Dianthus Therapeutics GAAP EPS of -$0.51 beats by $0.04
|
| Aug 8 |
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
|
| Jul 29 |
Dianthus: Improved Autoimmune Disorder Targeting With Classical Pathway Inhibition
|
| Jul 26 |
Baird starts Dianthus at outperform, cites lead drug DNTH103
|
| Jun 28 |
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)
|
| Jun 21 |
Dianthus Therapeutics: Complement System Candidate Not Sufficiently Derisked
|
| Jun 12 |
Dianthus wins FDA nod to start mid-stage trial for lead asset
|
| Jun 12 |
Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)
|
| May 30 |
Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference
|
